American Association for Cancer Research
Browse
15357163mct160004-sup-160511_2_supp_3469156_r6bnc8.ppt (66.5 kB)

Supplementary table 2. from In Silico Analysis Guides Selection of BET Inhibitors for Triple-Negative Breast Cancer Treatment

Download (66.5 kB)
figure
posted on 2023-04-03, 15:44 authored by Javier Pérez-Peña, Gemma Serrano-Heras, Juan Carlos Montero, Verónica Corrales-Sánchez, Atanasio Pandiella, Alberto Ocaña

Functional analyses of upregulated genes with a >4 fold changed. Specific functional categories were assigned by DAVID Bioinformatics Resources 6.7. Table 2 shows modified functions at 12 hours and table 3 at 24 hours.

Funding

Instituto de Salud Carlos III

ACEPAIN; AMAC, Diputación de Albacete and CRIS Cancer Foundation

Ministry of Economy and Competitiveness of Spain

AECC

Miguel Servet

History

ARTICLE ABSTRACT

Triple-negative breast cancer (TNBC) is an incurable disease with poor prognosis. At this moment, therapeutic options are limited to chemotherapy, and no targeted agent has reached the clinical setting. Bromodomain and extraterminal (BET) inhibitors are a new family of compounds that inhibit bromodomain-containing proteins affecting the expression of transcription factors, therefore modifying the expression of relevant oncogenic genes. In the present article, by using an in silico approach, we have identified the expression of upregulated transcription factors in TNBC compared with normal breast. Treatment with JQ1, a well-characterized BET inhibitor, modified some transcription factors, including DEP domain containing 1 (DEPDC), Forkhead box M1 (FOXM1), and Lim domain only 4 (LM04). In cell line models, administration of JQ1 or OTX015, another BET inhibitor, produced a significant antiproliferative effect and synergized with chemotherapies. Biochemical evaluation demonstrated an arrest at G1 as the main mechanism of action with a clear increase of p27. Addition of these compounds to chemotherapy induced apoptosis compared to each agent given alone. Evaluation of JQ1 in xenografted tumors in nude mice showed a profound antitumoral effect with a reduction of DEPDC, FOXM1, and LM04, in addition to an increase of p27. Globally, our data demonstrate the antitumor effect of this new family of compounds in TNBC, paving the way for its future clinical development. Mol Cancer Ther; 15(8); 1823–33. ©2016 AACR.

Usage metrics

    Molecular Cancer Therapeutics

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC